Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | DCK | P27707 | 8/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.30 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15468852 | 0.79 | ADORA2A (0.33) | ADORA2AADORA1 | |
| SCHEMBL12206794 | 0.79 | ADORA2A (0.36) | ADORA2AADORA1CDK1CCNB1CCNE1 | |
| SCHEMBL12894752 | 0.78 | EP300 (0.33) | ALBDCKEP300 | |
| SCHEMBL24538994 | 0.78 | TET2 (0.40) | ADORA2AADORA1CDK1CCNB1CCNE1 | |
| SCHEMBL21418602 | 0.78 | CDK1 (0.34) | ADORA2AADORA1CDK1CCNB1CCNE1 | |
| SCHEMBL10137834 | 0.78 | CDK1 (0.34) | ADORA2AADORA1CDK1CCNB1CCNE1 | |
| SCHEMBL18287861 | 0.78 | CDK1 (0.34) | ADORA2AADORA1CDK1CCNB1CCNE1 | |
| SCHEMBL22327308 | 0.76 | CDK1 (0.33) | ADORA2AADORA1CDK1CCNB1CCNE1 | |
| SCHEMBL12894749 | 0.76 | ALB (0.36) | ALBDCKEP300 | |
| SCHEMBL22815034 | 0.75 | CDK1 (0.33) | ADORA2AADORA1CDK1CCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-01-18 | — | — | US | disclosed |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3746452-B1 | STEREOSELECTIVE SYNTHESIS AND PROCESS FOR THE MANUFACTURING OF 2'-DEOXYNUCLEOSIDES | US HEALTH (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022127914-A1 | NUCLEOSIDE-THIODIPHOSPHATE-HEPTOSE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH ALPK1 ACTIVITY | PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) | 2022-06-23 | — | — | WO | disclosed |
| US-20210338696-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210246153-A1 | Nucleotide Analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-08-12 | — | — | US | disclosed |
| US-10688112-B2 | Lipid disulfide prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2019152459-A1 | STEREOSELECTIVE SYNTHESIS AND PROCESS FOR THE MANUFACTURING OF 2'-DEOXYNUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-02 | — | — | US | disclosed |
| US-9173893-B2 | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections | COCRYSTAL PHARMA, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9085599-B2 | 2′allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| US-8575119-B2 | 2′-chloroacetylenyl substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130078217-A1 | 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2013-03-28 | — | — | US | disclosed |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338696-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, GSTO1 | ADORA2A 822/4885ADORA1 1003/4885ALB 3271/4885 |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | ADORA2A 3655/4885ADORA1 1163/4885ALB 4486/4885 |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | NME2, HAVCR2, ENTPD5 | ADORA2A 10/4885ADORA1 42/4885ALB 3175/4885 |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | RNGTT, TYMP, SLC29A1 | ADORA2A 255/4885ADORA1 129/4885ALB 3889/4885 |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | ADORA2A 464/4885ADORA1 921/4885ALB 216/4885 |
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, SGMS2 | ADORA2A 875/4885ADORA1 1043/4885ALB 3591/4885 |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | ADORA2A 84/4885ADORA1 206/4885ALB 1912/4885 |
| US-10688112-B2 | Lipid disulfide prodrugs and uses related thereto | SMPD1, SGMS1, GSTO1 | ADORA2A 822/4885ADORA1 1003/4885ALB 3271/4885 |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | ADORA2A 84/4885ADORA1 206/4885ALB 1912/4885 |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | SMPD1, SGMS1, GSTO1 | ADORA2A 822/4885ADORA1 1003/4885ALB 3271/4885 |
| US-20130078217-A1 | 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES | DUT, HAVCR2, HCCS | ADORA2A 180/4885ADORA1 272/4885ALB 1917/4885 |
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | DDT, DPYD, DNPEP | ADORA2A 2696/4885ADORA1 3574/4885ALB 3460/4885 |
| US-20210246153-A1 | Nucleotide Analogs | NUDT1, DUT, DPYD | ADORA2A 408/4885ADORA1 478/4885ALB 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.